Predictive study of TWA1 mRNA expression in peripheral blood on the prognosis of patients with gastric cancer

doi:10.3877/cma.j.issn.1674-0793.2020.06.005

Abstract

Abstract:

Objective

To investigate the predictive value of peripheral blood TWA1 mRNA expression on the prognosis of patients with gastric cancer (GC).

Methods

A total of 97 GC patients treated in the Second People’s Hospital of Xining City from June 2016 to June 2017 were selected, and the TWA1 expression in peripheral blood was detected by real-time fluorescent quantitative PCR (RT-PCR). Patients were followed up and recorded for progression-free survival (PFS). The ROC curve was used to determine the threshold of peripheral blood TWA1 mRNA for PFS in GC patients. PFS of patients with different expression of TWA1 mRNA was compared. Finally, Cox regression analysis was used to analyze the influencing factors of patients’ PFS.

Results

The average follow-up time of all patients was (20.91±5.76) months, the follow-uprate was 94.79% with an average PFS of (21.83±5.13) months. The AUC for PFS of GC patients by TWA1 mRNA was 0.781 (95% CI: 0.687-0.875, P<0.001), and the Cut-off value was 1.27. PFS in patients with high TWA1 mRNA expression was significantly shorter (χ2=14.415, P<0.01). Lymph node metastasis (HR=3.328, 95% CI: 2.098-5.971, P=0.044), TNM Ⅲ-Ⅳ (HR=3.400, 95% CI: 1.114-4.795, P=0.011), and high expression of TWA1 mRNA in peripheral blood (HR=7.429, 95% CI: 1.711-32.263, P=0.007) were independent risk factors for PFS.

Conclusion

The expression of TWA1 in peripheral blood has a significant effect on the prognosis of GC patients, which has good predictive value for the prognosis ofGC patients.

Key words: Stomach neoplasms, TWA1, E3 ubiquitin ligase complex, Prognosis, Predictive value

Shifang Cheng, Yongyun Mao, Shengye Tang, Zhibin Hou. Predictive study of TWA1 mRNA expression in peripheral blood on the prognosis of patients with gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(06): 421-424.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.06.005

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I06/421

Figures/Tables 4

References 16

[1]	Kaito A, Kinoshita T, Tokunaga M, et al. Prognostic factors and recurrence pattern of far-advanced gastric cancer with pathologically-positive para-aortic lymph nodes[J]. Anticancer Res, 2017, 37(7): 3685-3692.
[2]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[3]	Yang H, Fu H, Wang B, et al. Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer[J]. Mol Carcinog, 2018, 57(9): 1223-1236.
[4]	Francis O, Baker GE, Race PR, et al. Studies of recombinant TWA1 reveal constitutive dimerization[J]. Biosci Rep, 2017, 37(1): pii: BSR20160401.
[5]	Ore F, Fujun H, Adams JC, et al. Molecular phylogeny of a RING E3 Ubiquitin ligase, conserved in eukaryotic cells and dominated by homologous components, the Muskelin/RanBPM/CTLH complex[J]. PLoS One, 2013, 8(10): e75217.
[6]	Lu Y, Xie S, Zhang W, et al. Twa1/Gid8 is a β-catenin nuclear retention factor in Wnt signaling and colorectal tumorigenesis[J]. Cell Res, 2017, 27(12): 1422-1440.
[7]	Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27(suppl 5): v38-v49.
[8]	曹一鑫, 李小琴, 王宏宇, 等. Tensin1蛋白与胃癌临床病理特征及预后的关系[J]. 中华消化外科杂志, 2018, 17(6): 612-618.
[9]	de Araujo TS, Almeida MS. 1H, 13C and 15N chemical shift assignment of lissencephaly-1 homology (LisH) domain homodimer of human two-hybrid-associated protein 1 with RanBPM (Twa1)[J]. Biomol NMR Assign, 2018, 12(1): 99-102.
[10]	Huffman N, Palmieri D, Coppola V. The CTLH complex in cancer cell plasticity[J]. J Oncol, 2019, 2019: 4216750.
[11]	Hou G, Yuan X, Li Y, et al. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway[J]. Invest New Drugs, 2020, 38(2): 329-339.
[12]	Kilic L, Ordu C, Yildiz I, et al. Current adjuvant treatment modalities for gastric cancer: from history to the future[J]. World J Gastrointest Oncol, 2016, 8(5): 439-449.
[13]	Cheng L, Wang P, Yang S, et al. Identification of genes with a correlation between copy number and expression in gastric cancer[J]. BMC Med Genomics, 2012, 5(1): 14.
[14]	Tessari A, Parbhoo K, Pawlikowski M, et al. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients[J].Oncogene, 2018, 37(50): 6463-6476.
[15]	Jiang F, Shi Y, Lu H, et al. Armadillo repeat-containing protein 8 (ARMC8) silencing inhibits proliferation and invasion in osteosarcoma cells[J]. Oncol Res, 2016, 24(5): 381-389.
[16]	Xiong J, Feng Z, Li Z, et al. Overexpression of TWA1 predicts poor prognosis in patients with gastric cancer[J]. Pathol Res Pract, 2019, 215(11): 152594.

组别	例数	性别(例)		年龄(岁，±s)	瘤体最大直径(cm，±s)	血管浸润(例)	神经浸润(例)
组别	例数	男	女	年龄(岁，±s)	瘤体最大直径(cm，±s)	血管浸润(例)	神经浸润(例)
PFS组	63	40	25	58.07±7.24	2.56±0.75	21	30
非PFS组	28	16	10	58.31±6.14	2.96±0.85	15	13
统计值		χ²=0.129		t=0.154	t=2.645	χ²=7.569	χ²=0.078
P值		0.719		0.878	0.011	0.005	0.778
组别	淋巴结转移(例)	TWA1 mRNA(±s)	肿瘤位置(例)		TNM分期(例)		术后辅助化疗(例)
组别	淋巴结转移(例)	TWA1 mRNA(±s)	贲门	胃体胃窦	Ⅰ~Ⅱ	Ⅲ~Ⅳ	术后辅助化疗(例)
PFS组	33	1.07±0.26	30	33	43	20	46
非PFS组	24	1.37±0.27	15	13	7	21	17
统计值	χ²=9.203	t=5.003	χ²=0.274		χ²=14.651		χ²=1.377
P值	0.002	<0.001	0.601		<0.001		0.241

组别	例数	性别(例)		年龄(岁，±s)	瘤体最大直径(cm，±s)	血管浸润(例)	神经浸润(例)
组别	例数	男	女	年龄(岁，±s)	瘤体最大直径(cm，±s)	血管浸润(例)	神经浸润(例)
PFS组	63	40	25	58.07±7.24	2.56±0.75	21	30
非PFS组	28	16	10	58.31±6.14	2.96±0.85	15	13
统计值		χ²=0.129		t=0.154	t=2.645	χ²=7.569	χ²=0.078
P值		0.719		0.878	0.011	0.005	0.778
组别	淋巴结转移(例)	TWA1 mRNA(±s)	肿瘤位置(例)		TNM分期(例)		术后辅助化疗(例)
组别	淋巴结转移(例)	TWA1 mRNA(±s)	贲门	胃体胃窦	Ⅰ~Ⅱ	Ⅲ~Ⅳ	术后辅助化疗(例)
PFS组	33	1.07±0.26	30	33	43	20	46
非PFS组	24	1.37±0.27	15	13	7	21	17
统计值	χ²=9.203	t=5.003	χ²=0.274		χ²=14.651		χ²=1.377
P值	0.002	<0.001	0.601		<0.001		0.241

变量	β	SE	Wald	P值	HR	95% CI
性别构成(男vs女)	0.065	0.480	0.018	0.893	1.067	0.416~2.735
年龄(实测值)	0.012	0.030	0.155	0.694	1.012	0.954~1.073
瘤体最大直径(实测值)	0.221	0.273	0.649	0.420	1.246	0.729~2.129
血管浸润(是vs否)	0.298	0.476	0.391	0.532	1.347	0.292~1.886
神经浸润(是vs否)	0.123	0.432	0.081	0.775	1.131	0.485~2.640
淋巴结转移(是vs否)	1.175	0.584	4.040	0.044	3.328	2.098~5.971
TWA1 mRNA(实测值)	2.005	0.749	7.164	0.007	7.429	1.711~32.263
肿瘤位置(贲门vs胃体胃窦)	-0.582	0.435	1.784	0.182	0.559	0.238~1.312
TNM分期(Ⅲ~ⅣvsⅠ~Ⅱ)	1.224	0.484	6.400	0.011	3.400	1.114~4.759
术后辅助化疗(是vs否)	-0.702	0.481	2.126	0.145	0.459	0.785~5.181

变量	β	SE	Wald	P值	HR	95% CI
性别构成(男vs女)	0.065	0.480	0.018	0.893	1.067	0.416~2.735
年龄(实测值)	0.012	0.030	0.155	0.694	1.012	0.954~1.073
瘤体最大直径(实测值)	0.221	0.273	0.649	0.420	1.246	0.729~2.129
血管浸润(是vs否)	0.298	0.476	0.391	0.532	1.347	0.292~1.886
神经浸润(是vs否)	0.123	0.432	0.081	0.775	1.131	0.485~2.640
淋巴结转移(是vs否)	1.175	0.584	4.040	0.044	3.328	2.098~5.971
TWA1 mRNA(实测值)	2.005	0.749	7.164	0.007	7.429	1.711~32.263
肿瘤位置(贲门vs胃体胃窦)	-0.582	0.435	1.784	0.182	0.559	0.238~1.312
TNM分期(Ⅲ~ⅣvsⅠ~Ⅱ)	1.224	0.484	6.400	0.011	3.400	1.114~4.759
术后辅助化疗(是vs否)	-0.702	0.481	2.126	0.145	0.459	0.785~5.181

Please choose a citation manager

Content to export